1. Home
  2. JANX

as 03-28-2025 3:38pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Founded: 2017 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 2.2B IPO Year: 2021
Target Price: $91.25 AVG Volume (30 days): 833.0K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.28 EPS Growth: N/A
52 Week Low/High: $28.91 - $71.71 Next Earning Date: 05-06-2025
Revenue: $10,588,000 Revenue Growth: 30.99%
Revenue Growth (this year): -70.64% Revenue Growth (next year): 318.21%

JANX Daily Stock ML Predictions

Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
RA CAPITAL MANAGEMENT, L.P. JANX Director10% Owner Mar 5 '25 Buy $30.92 824,041 $25,342,964.88 10,141,287
Meyer Andrew Hollman JANX Chief Business Officer Mar 3 '25 Sell $32.37 3,334 $107,174.38 83,040
Meyer Andrew Hollman JANX Chief Business Officer Feb 3 '25 Sell $42.82 3,334 $140,999.37 83,040
Campbell David Alan JANX President and CEO Jan 7 '25 Sell $60.00 5,000 $300,004.00 293,054
Meyer Andrew Hollman JANX Chief Business Officer Jan 2 '25 Sell $55.63 13,334 $731,785.25 83,040

Share on Social Networks: